Like other sulfonylureas,<unk>  acts to increase the secretion of insulin, so it is only effective in patients who have some pancreatic beta cell function. It can cause relatively long episodes of hypoglycemia; this is one reason why shorter-acting sulfonylureas such as gliclazide or tolbutamide are used instead. The risk of hypoglycemia makes this drug a poor choice for the elderly and patients with mild to moderate hepatic and renal impairment.<unk>  is also used in partial central diabetes insipidus.
Chlorpropamide
Metkefamide
Doxepin
Beclamide
Mebanazine
Halofantrine
Amrinone
Bromazine